http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I267517-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1f877e65a891ee9543f98b4d5c8b1c66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b10c314f4b07d581ea1e7ea8ce26c65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c142ec98cd5c96b9181a29eb8c09fbd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate | 2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af884322303e801d8b3143a31ea8d12c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55bc2bbb1d7546b99d8f4e48211a4dc8 |
| publicationDate | 2006-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-I267517-B |
| titleOfInvention | Method for producing human antibodies with properties of agonist, antagonist, or inverse agonist |
| abstract | A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method for use in the screening of CD152 ligands that yield pharmacological effects. |
| priorityDate | 2004-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 360.